Comparison Between Second- and Third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as First-line Treatment in Patients With Non-small-cell Lung Cancer: A Retrospective Analysis
| Autor: | Takahiko Nakamura, Kenjiro Tsuruoka, Kiyoe Kanaoka, Yosuke Tamura, Yasuhito Fujisaka, Soichiro Ikeda, Tomoya Funamoto, Masafumi Imanishi, Isao Goto, Akihisa Imagawa, Hiroyuki Tsuji, Sho Mitsuya, Ninso Matsunaga |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty Lung Neoplasms Afatinib T790M Carcinoma Non-Small-Cell Lung Internal medicine medicine Humans Osimertinib Epidermal growth factor receptor Lung cancer Protein Kinase Inhibitors Aged Retrospective Studies Aged 80 and over Acrylamides Aniline Compounds biology business.industry Hazard ratio General Medicine Middle Aged Prognosis medicine.disease Confidence interval respiratory tract diseases ErbB Receptors Survival Rate Mutation biology.protein Female Non small cell business Follow-Up Studies medicine.drug |
| Zdroj: | Anticancer Research. 41:5137-5145 |
| ISSN: | 1791-7530 0250-7005 |
| Popis: | BACKGROUND For epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), administration of EGFR tyrosine kinase inhibitors (TKIs) is mandatory to prolong survival. To date, a comparison of second- and third-generation EGFR-TKIs has not been reported as far as we are aware. PATIENTS AND METHODS We retrospectively investigated the survival time of patients diagnosed with EGFR-mutated advanced or recurrent NSCLC who had received afatinib, a second-generation EGFR-TKI, or osimertinib, a third-generation EGFR-TKI, as the first-line treatment. RESULTS Among the 49 patients included in the study, 15 received afatinib and 34 received osimertinib. No significant differences in overall survival were observed between the two groups [afatinib vs. osimertinib=36 vs. 33 months (hazard ratio=2.917, 95% confidence interval=0.780-10.905; p=0.112)]. T790M mutation was detected in three of the patients in the afatinib group, and all three subsequently received osimertinib. The median overall survival of these three patients and of the 12 without the mutation were 63 and 36 months, respectively. CONCLUSION There was no apparent difference in the effect on survival between second- and third-generation EGFR-TKIs, whereas the sequential administration of second- followed by third-generation EGFR-TKIs appeared to confer a better long-term prognosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|